Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227883 · ClinicalTrials.gov registry record · Early Phase 1
Secretome Treatment for Facial Rejuvenation
A Early Phase 1 study of Stem Cell and Rejuvenation, sponsored by Acorn Biolabs.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07227883: Recruiting Early Phase 1 study of Stem Cell and Rejuvenation, sponsored by Acorn Biolabs.
NCT07227883 is a Early Phase 1 study of Stem Cell and Rejuvenation that is actively recruiting participants, run by Acorn Biolabs. The registered enrollment target is 24 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227883, a Early Phase 1 study of Stem Cell and Rejuvenation, is actively recruiting participants, sponsored by Acorn Biolabs.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Secretome treatment for facial rejuvenation
Primary Outcome
Adverse events and expected treatment effects will be collected at each time point. Spontaneously reported adverse events will also be collected.
Conditions Studied
Interventions
- OTHER Autologous Hair Follicle-Derived Secretome
- OTHER Control Saline
Study Locations (1)
California
- Steve Yoelin, MD - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-12-20 |
| Phase | Early Phase 1 |
What NCT07227883 shows while recruiting
NCT07227883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower).
The record links to 4 conditions, with Stem Cell appearing as the primary indexed condition, and to 2 interventions - of which Autologous Hair Follicle-Derived Secretome is the first listed.
NCT07227883 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07227883 about?
NCT07227883 is a clinical study titled "Secretome Treatment for Facial Rejuvenation". Secretome treatment for facial rejuvenation
What is the current status of trial NCT07227883?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2025-12-15. Estimated completion is 2026-12-20.
What conditions does trial NCT07227883 study?
This clinical trial studies the following conditions: Stem Cell, Rejuvenation, Facial Aging, Stem Cell Banking.
What interventions are being tested in trial NCT07227883?
The interventions under investigation include: Autologous Hair Follicle-Derived Secretome (OTHER), Control Saline (OTHER).
Who is sponsoring clinical trial NCT07227883?
This trial is sponsored by Acorn Biolabs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227883 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07227883's enrollment target sits among peer trials
24 1037th of 2000 higher than 914 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI